CrystecPharma

CrystecPharma applies the latest supercritical fluid technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies. Crystec supercritical fluid technologies can be applied to both small drug molecules and biotechnologically sourced drugs.

Our services include crystal form screening and particle design, addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. We are also engaged in in-house programmes to develop improved small and large molecule therapeutic products.

Come and see us at booth #73

Company Type
Dr Lyn Daintree
Dr Catherine Hunter

Datatrial

Datatrial is an oncology-focused boutique clinical data organization that provides the reliability of a big company, but the personalized service and flexibility of a more nimble provider. Whether you want your study conducted in paper or through our own innovative eClinical technologies, we design your study with insight and expertise, backed by comprehensive data management, bio-statistical and consulting services. By bridging the gap between the promise of outsourcing and the way results are delivered, we make your clinical study less of a trial.

Come and see us at booth #72

Company Type
Ms Julie Wright
Mr Lewis Baird
Ms Emma Banks

Diamond Pharma Services Ltd

Diamond Pharma Services is a leading technical and scientific consulting group of companies serving the biotechnology and pharmaceutical industry. Our emphasis is on the following areas:

•    Regulatory Affairs: From Product Concept to Registration and Beyond
•    Product Development: Nonclinical, CMC and Clinical Aspects
•    Pharmacovigilance: Clinical trial (Phase I-IV), Post-Marketing and QPPV Services
•    Compliance: GLP, GMP, GCP and QP Services

Our clients range from virtual start-up companies to the largest multi-national corporations. Our expertise includes products of recombinant DNA and hybridoma technology, nucleotide based products (RNA and DNA), synthetic peptides, chemical entities (innovative and generic), vaccines (therapeutic and prophylactic), blood products and advanced therapy medicinal products (gene and cell therapy products).

We have sophisticated and well-equipped office facilities and a state-of-the-art IT system. Our IT system includes a fully validated in-house eCTD system (Extedo) and safety database (ARISg). The company was founded in 2005 by Dr. Maureen Graham, formerly Director of Regulatory Affairs at Amgen. Our specialised team of more than 27 professionals includes those with a broad and varied industry experience and former regulators, offering both breadth and depth of expertise, from which our clients can benefit.  

Contact details:

Paul Cronin
Director of Business Development
Diamond Pharma Services Limited
No 4 East Wing, Gemini House
Flex Meadow, Harlow
Essex, CM19 5TJ
United Kingdom
Tel:     +44 (0)1279 441616
Fax:     +44 (0)1279 418964
Email:    pcronin@diamondpharmaservices.com
Web:    www.diamondpharmaservices.com

Come and see us at booth #73

Mr Paul Cronin

Epistem

Epistem is a biotechnology company with a specialist understanding of epithelial tissue and stem cell analyses.

The Contract Research Division delivers innovative preclinical research services in the areas of oncology, mucositis, inflammation, wound healing and skincare.

Highlights include 1st in class services in:

Oncology: We have a particular focus in developing preclinical in vivo models of Oncology that are clinically relevant. Some of these include novel models of Leukemia, orthotopic colon, orthotopic lung, orthotopic breast, and novel models of prostate cancer.

Inflammation: We are highly experienced in the field of Inflammatory bowel disease (IBD) and offer 3 preclinical models of the disease: Adoptive T-cell transfer (chronic), DSS (acute) and TNBS (acute). We are also now offering in vitro inflammation assays, and are developing in vivo models of RA.

Mucositis: World renowned experience in Oral and Intestinal Mucositis. Epistem can progress a potential therapeutic candidate through mechanism of action studies, dose optimisation and scheduling, to functional efficacy studies.

Plucked Hair Biomarker Platform: Patient plucked hair is an ideal surrogate tissue that can be used to measure direct response to drug treatment for biomarker studies. Epistem has developed an innovative, non-invasive plucked hair biomarker platform that enables measurment of target changes in response to drug (including phosphorylated proteins) within a single plucked human hair.

Come and see us at booth #73

Company Type
Ms Julie Foster
Business Development Manager Europe 

Glythera

Glythera Limited is a biotechnology company specializing in the development of enhanced protein/peptide therapeutics through the use of advanced glycosylation and conjugation technologies. Originally spun-out from the University of Bath, the Company relocated to the Newcastle-upon-Tyne INEX incubator facility in 2012, following investment from the IP Group and the Finance for Business North East Technology Fund. Gylthera's core technologies - Permalink and Permacarb - allow the selective and stable functionalization and glycosylation of biopharmaceuticals for improved stability, bioavailability and efficacy.

Come and see us at booth #73

Website:
www.glythera.com
Company Type
Dr David Simpson

Haemostatix

Haemostatix is developing first-in-class clotting agents or ‘haemostats’, for the treatment of bleeding in surgery and trauma. The company has pioneered a new approach to the control of bleeding that is based on a peptide that binds to the clotting protein fibrinogen, inducing the rapid and targeted formation of clots. This innovative technology platform is being used to develop a pipeline of topical and systemic products to prevent or control different forms of bleeding.

Haemostatix's products include:  PeproStat™, a topical haemostat that is applied directly to wounds to rapidly control bleeding during surgery or trauma. PeproStat has a novel mode of action that is fast and effective. The product is also stable in liquid form in contrast to the main competitor, blood-derived thrombin, enabling the development of ready-to-use formulations, a key unmet need.  HaemoPlax™ is a platelet substitute in development for the prevention of bleeding in leukaemic patients with platelet deficiency or ‘thrombocytopenia'. HXTC901 is a 'pro-drug' version of HaemoPlax that is activated by the enzyme thrombin at a wound site. HXTC 901 is designed to control more active bleeds in surgery or trauma.  

Haemostatix is based at BioCity Nottingham, UK, in the City’s Creative Quarter

Company Type
Dr Ben Nichols

ICT Biosciences

ICT Biosciences is the business arm of the Institute of Cancer Therapeutics for the delivery of all research and business activity. The Institute of Cancer Therapeutics houses a multidisciplinary team of researchers in the field of drug design, synthesis, screening and pharmacology. Our purpose built institute is configured to integrate all the elements of the preclinical drug discovery process, in keeping with our mission to research and develop new treatments with a focus on cancer and other proliferative diseases.

Come and see us at booth #73

Company Type
Mr Stuart Nelson

Molecular Profiles

Molecular Profiles provides contract development and manufacturing services for clients globally. We specialise in early development and clinical trial manufacturing up to phase IIb and have expertise in understanding and formulating drug candidates that possess challenging characteristics. Our experience and capabilities provide the following product outputs; solid oral dosage forms for immediate and modified release, topicals, liquids and DPI products, we also utilise Xcelodose precision dosing for rapid development of low dose clinical trial supplies. Our facilities can handle potent candidates and controlled drug substances.

We utilise the most appropriate formulation strategy for your drug candidate based around your quality target product profile. For example in the formulation development of poorly water soluble / bioavailable candidates this may include our expertise in nanomilling, spray drying, SEDDS, SMEDDS and other absorption enhancing approaches.

Underpinning all of our development and manufacturing expertise is a wealth of experience in materials characterisation and analysis which has been utilised to solve some of the most complex challenges in API and formulation development. Our renowned problem to solution approach has been utilised on over a 1000 development projects and also in establishing the patent position for commercialised blockbuster products.

Company Type
Mr Peter Farmer

Nova Language Services

Come and see us at booth #73

Mr Arun Mathew
Mr Cristobal Perez

Pathology Diagnostics

Pathology Diagnostics Ltd. based in Cambridge UK, is a leading industry accredited research organisation providing tissue laboratory and diagnostic services to international pharmaceutical, biotechnology and companion diagnostics clients. We provided centralized integrated drug and biomarker testing on human and rodent tissues including IHC assay validation, digital whole slide scanning and fully automated quantitative image analysis enabling faster higher quality results at a fraction of the cost of traditional pathology approaches. We have a proven track record in early discovery & preclinical studies, clinical trials, biomarker and companion diagnostic R&D enabling you to make objective data driven decisions on your studies. Our team consists of on-site and remote medical and veterinary pathologists plus research scientists with several decades’ pathology and research experience. We hold full industry accreditation so that you may be assured that the results we generate are accurate consistent and reliable.

At Pathology Diagnostics Ltd we are embracing developments in digital pathology to become a leading reference laboratory for biomarker testing for personalized medicine. Over the last few years we have e valuated over 130 biomarkers in > 75,000 patient samples from a wide variety of tumour and normal tissues in oncology, cardiovascular, metabolic, neurodegenerative & respiratory disease.

Come and visit us at booth 73.

Dr Madhuri Warren
Dr Josiah Dungwa